Clinical Trials Finder

Independent ClinicalTrials.gov directory

Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 10:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Hormone Receptor/Growth Factor Receptor-Negative Breast Cancer Clear all

Active, not recruiting Phase 2 Interventional

PF-07104091 as a Single Agent and in Combination Therapy

NCT04553133

View directory record Official record

Conditions: Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer
Interventions: PF-07104091 monotherapy dose escalation, PF-07104091 + palbociclib + fulvestrant, PF-07104091 + palbociclib + letrozole, PF-07104091 monotherapy dose expansion (ovarian), PF-07104091 monotherapy dose expansion (SCLC), PF-07104091 + Fulvestrant (post CDK4/6), PF-0704091 + Fulvestrant (post CDK4/6); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older

Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 17
States / cities: Clive, Iowa • Des Moines, Iowa • Louisville, Kentucky + 7 more

Source: ClinicalTrials.gov public record

Updated May 5, 2026 · Synced May 21, 2026, 10:13 PM EDT

Recruiting Phase 2 Interventional

PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)

NCT07222215

View directory record Official record

Conditions: Estrogen-receptor-positive Breast Cancer, Metastatic Breast Cancer, Breast Cancer, Hormone Receptor Positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, HER2- Breast Cancer, ESR1 Gene Mutation, ER Wildtype, Breast Neoplasms
Interventions: Capecitabine, Elacestrant; Drug
Lead sponsor: Kristina A. Fanucci; Other
Eligibility: 18 Years and older

Enrollment: 297 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Source: ClinicalTrials.gov public record

Updated Jan 21, 2026 · Synced May 21, 2026, 10:13 PM EDT

Completed No phase listed Observational Results available

Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.

NCT06086340

View directory record Official record

Conditions: Breast Cancer
Interventions: Palbociclib, Aromatase Inhibitor; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 65 Years and older

Enrollment: 779 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New York, New York

Source: ClinicalTrials.gov public record

Updated Nov 17, 2025 · Synced May 21, 2026, 10:13 PM EDT

Completed Phase 2 Interventional

A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants

NCT05963984

View directory record Official record

Conditions: Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer
Interventions: Samuraciclib, Fulvestrant; Drug
Lead sponsor: Carrick Therapeutics Limited; Industry
Eligibility: 18 Years and older

Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 5
States / cities: Ocala, Florida • Baltimore, Maryland • Kansas City, Missouri + 2 more

Source: ClinicalTrials.gov public record

Updated Dec 25, 2025 · Synced May 21, 2026, 10:13 PM EDT

Completed No phase listed Observational

A Study to Learn About the Relationship Between Hepatic Impairment and Myelosuppression (Decreased Bone Marrow Function) in Breast Cancer Patients Treated With the Study Medicine Palbociclib (Pal-bow-sai-klib)

NCT05912933

View directory record Official record

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Pfizer; Industry
Eligibility: 0 Years and older

Enrollment: 733 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: New York, New York

Source: ClinicalTrials.gov public record

Updated Jun 12, 2025 · Synced May 21, 2026, 10:13 PM EDT

Completed Phase 1 Interventional

WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor

NCT03854903

View directory record Official record

Conditions: Metastatic Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Hormone Receptor Positive Breast Cancer
Interventions: Palbociclib, Bosutinib, Fulvestrant; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older · Female only

Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Source: ClinicalTrials.gov public record

Updated Feb 5, 2025 · Synced May 21, 2026, 10:13 PM EDT

Withdrawn Phase 1Phase 2 Interventional

Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC

NCT05191004

View directory record Official record

Conditions: Advanced Breast Cancer, Metastatic Breast Cancer, Breast Cancer, Breast Carcinoma, Cancer of the Breast, Cancer of Breast, Malignant Tumor of Breast, Breast Tumor
Interventions: NUV-422, Fulvestrant; Drug
Lead sponsor: Nuvation Bio Inc.; Industry
Eligibility: 18 Years and older

Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 5
States / cities: Anaheim, California • Fountain Valley, California • Canton, Ohio + 2 more

Source: ClinicalTrials.gov public record

Updated Jul 10, 2023 · Synced May 21, 2026, 10:13 PM EDT

Recruiting Phase 3 Interventional

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

NCT06966700

View directory record Official record

Conditions: Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
Interventions: Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication, Carboplatin, Paclitaxel, Doxorubicin, Epirubicin, Cyclophosphamide, Capecitabine, Olaparib; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older

Enrollment: 2,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 51
States / cities: Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 45 more

Source: ClinicalTrials.gov public record

Updated May 14, 2026 · Synced May 21, 2026, 10:13 PM EDT

Active, not recruiting Phase 3 Interventional

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

NCT05840211

View directory record Official record

Conditions: Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer
Interventions: Sacituzumab Govitecan-hziy, Paclitaxel, Nab-paclitaxel, Capecitabine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older

Enrollment: 654 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 30
States / cities: Chandler, Arizona • Los Angeles, California • Palo Alto, California + 25 more

Source: ClinicalTrials.gov public record

Updated Oct 2, 2025 · Synced May 21, 2026, 10:13 PM EDT

Terminated Phase 1 Interventional

A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors

NCT06264921

View directory record Official record

Conditions: Solid Tumor, Solid Tumor, Adult, Advanced Solid Tumor, Metastatic Tumor, Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Metastatic Ovarian Carcinoma, Endometrial Cancer, Endometrial Neoplasms, Endometrial Diseases, Metastatic Endometrial Cancer, Metastatic Endometrial Carcinoma, Advanced Endometrial Carcinoma, Advanced Ovarian Carcinoma, Gastric Cancer, Advanced Gastric Carcinoma, Metastatic Gastric Cancer, Metastatic Gastric Carcinoma, Small-cell Lung Cancer, Small Cell Lung Carcinoma, Triple Negative Breast Cancer, Triple Negative Breast Neoplasms, Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Carcinoma, CCNE1 Amplification, Hormone Receptor Negative Breast Carcinoma, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Progesterone-receptor-positive Breast Cancer
Interventions: NKT3447; Drug
Lead sponsor: NiKang Therapeutics, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 8
States / cities: San Francisco, California • Denver, Colorado • Celebration, Florida + 5 more

Source: ClinicalTrials.gov public record

Updated Sep 24, 2025 · Synced May 21, 2026, 10:13 PM EDT

Recruiting Phase 1Phase 2 Interventional

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

NCT05985655

View directory record Official record

Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC), Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma, Triple Negative Breast Cancer (TNBC)
Interventions: GTAEXS617, SoC; Drug
Lead sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 4
States / cities: Los Angeles, California • Grand Rapids, Michigan • San Antonio, Texas + 1 more

Source: ClinicalTrials.gov public record

Updated Apr 22, 2026 · Synced May 21, 2026, 10:13 PM EDT

Recruiting Phase 1 Interventional

FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer

NCT05304962

View directory record Official record

Conditions: Breast Cancer
Interventions: RGT-419B, RGT-419B in combination with hormonal therapy; Drug
Lead sponsor: Regor Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 8
States / cities: La Jolla, California • Los Angeles, California • Port Saint Lucie, Florida + 5 more

Source: ClinicalTrials.gov public record

Updated Apr 1, 2026 · Synced May 21, 2026, 10:13 PM EDT

Recruiting Phase 2 Interventional

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

NCT06369285

View directory record Official record

Conditions: Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer
Interventions: Alisertib, Endocrine therapy; Drug
Lead sponsor: Puma Biotechnology, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 35
States / cities: Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 28 more

Source: ClinicalTrials.gov public record

Updated Dec 9, 2025 · Synced May 21, 2026, 10:13 PM EDT

Completed Phase 2 Interventional Results available

Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer

NCT02668666

View directory record Official record

Conditions: Hormone Receptor Positive Malignant Neoplasm of Breast, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Estrogen Receptor Positive Breast Cancer, Progesterone Receptor Positive Tumor, Metastatic Breast Cancer
Interventions: Palbociclib, Tamoxifen; Drug
Lead sponsor: Oana Danciu, MD; Other
Eligibility: 18 Years and older

Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 7
States / cities: Chicago, Illinois • Lansing, Michigan • Minneapolis, Minnesota + 4 more

Source: ClinicalTrials.gov public record

Updated Jan 19, 2026 · Synced May 21, 2026, 10:13 PM EDT

Completed Phase 2 Interventional Results available

Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer

NCT01441947

View directory record Official record

Conditions: Breast Cancer
Interventions: Cabozantinib, Fulvestrant; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older

Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 4
States / cities: Boston, Massachusetts • New York, New York

Source: ClinicalTrials.gov public record

Updated May 24, 2025 · Synced May 21, 2026, 10:13 PM EDT

Completed No phase listed Observational Results available

Treatment Patterns and Clinical Outcomes Among Patients With HR+/HER2- mBC Receiving Palbociclib Combination Therapy in the US Community Oncology Setting.

NCT04460911

View directory record Official record

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older

Enrollment: 317 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: New York, New York

Source: ClinicalTrials.gov public record

Updated Jan 10, 2024 · Synced May 21, 2026, 10:13 PM EDT

Terminated Phase 2 Interventional

Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)

NCT06408168

View directory record Official record

Conditions: Hormone Receptor-positive Human Epidermal Growth Factor 2-negative, Metastatic Invasive LObular Carcinoma
Interventions: Fulvestrant, Repotrectinib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older

Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Source: ClinicalTrials.gov public record

Updated Jan 4, 2026 · Synced May 21, 2026, 10:13 PM EDT

Terminated Phase 1 Interventional Results available

Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer

NCT02964507

View directory record Official record

Conditions: Neoplasms
Interventions: GSK525762, Placebo, Fulvestrant; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older · Female only

Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 15
States / cities: Birmingham, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 12 more

Source: ClinicalTrials.gov public record

Updated Aug 28, 2024 · Synced May 21, 2026, 10:13 PM EDT

Active, not recruiting Phase 2 Interventional Results available

A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

NCT04225117

View directory record Official record

Conditions: Locally Advanced or Metastatic Malignant Solid Tumors
Interventions: enfortumab vedotin, pembrolizumab; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 329 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 29
States / cities: Tucson, Arizona • San Francisco, California • Aurora, Colorado + 23 more

Source: ClinicalTrials.gov public record

Updated Apr 12, 2026 · Synced May 21, 2026, 10:13 PM EDT

Active, not recruiting Phase 1 Interventional

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

NCT06084481

View directory record Official record

Conditions: Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancers, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Cancer, Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer, Head and Neck Squamous-Cell Carcinoma, Platinum Resistant High Grade Epithelial Ovarian Cancer
Interventions: ABBV-400, Itraconazole (ITZ); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older

Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 20
States / cities: Duarte, California • San Francisco, California • Aurora, Colorado + 15 more

Source: ClinicalTrials.gov public record

Updated Jan 19, 2026 · Synced May 21, 2026, 10:13 PM EDT

Recruiting Phase 3 Interventional

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

NCT07062965

View directory record Official record

Conditions: Breast Cancer
Interventions: PF-07248144, Fulvestrant, Everolimus, Exemestane; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older

Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 102
States / cities: Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 85 more

Source: ClinicalTrials.gov public record

Updated May 5, 2026 · Synced May 21, 2026, 10:13 PM EDT

Recruiting Phase 1Phase 2 Interventional

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

NCT05735080

View directory record Official record

Conditions: Breast Cancer, Breast Cancer Metastatic, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Ovarian Cancer, CCNE1 Amplification, Solid Tumor, Advanced Cancer, Metastatic Cancer
Interventions: INX-315, Fulvestrant, Abemaciclib; Drug
Lead sponsor: Incyclix Bio; Industry
Eligibility: 18 Years and older

Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 15
States / cities: Orlando, Florida • Atlanta, Georgia • Augusta, Georgia + 10 more

Source: ClinicalTrials.gov public record

Updated Mar 31, 2026 · Synced May 21, 2026, 10:13 PM EDT

Completed Phase 1Phase 2 Interventional Results available

A Study of ZN-c5 in Subjects With Breast Cancer

NCT03560531

View directory record Official record

Conditions: Breast Cancer
Interventions: ZN-c5, Palbociclib; Drug
Lead sponsor: Zeno Alpha Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 11
States / cities: Tucson, Arizona • Los Angeles, California • Bethesda, Maryland + 6 more

Source: ClinicalTrials.gov public record

Updated Aug 8, 2024 · Synced May 21, 2026, 10:13 PM EDT

Recruiting Phase 2 Interventional

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

NCT06797635

View directory record Official record

Conditions: Breast Neoplasms, Breast Cancer
Interventions: Patritumab deruxtecan, Pembrolizumab, Paclitaxel, Carboplatin, Doxorubicin hydrochloride, Epirubicin hydrochloride, Cyclophosphamide, Capecitabine, Olaparib; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older

Enrollment: 372 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 8
States / cities: Santa Monica, California • Skokie, Illinois • Billings, Montana + 5 more

Source: ClinicalTrials.gov public record

Updated May 19, 2026 · Synced May 21, 2026, 10:13 PM EDT